ERYP Erytech Pharma S.A.

-0.49  -7%
Previous Close 7.42
Open 7
Price To Book 0.6
Market Cap 124307118
Shares 17,937,535
Volume 201
Short Ratio
Av. Daily Volume 2,520

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial completed.
Phase 3 enrollment to commenced soon - noted September 10, 2018.
Eryaspase (GRASPA)
Pancreatic cancer
Upcoming meeting with FDA to discuss next steps.
Eryaspase (GRASPA)
Acute lymphoblastic leukemia (ALL) - front line
Phase 2 enrollment to commence 4Q 2018. Interim data due 2H 2019.
Eryaspase (GRASPA)
Triple-Negative Breast Cancer (TNBC)
Phase 2b planned for 1H 2019.
Eryaspase (GRASPA)
Pancreatic cancer - first-line